MedTrace Logo

Losartan for the Treatment of Pediatric NAFLD

NCT03467217 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2021-10-21

Study results available
· View outcomes & findings →

Summary

A multicenter, randomized, double masked, placebo-controlled, parallel treatment groups phase 2 trial of losartan for pediatric nonalcoholic fatty liver disease (NAFLD).

Conditions

  • NAFLD - Nonalcoholic Fatty Liver Disease

Interventions

DRUG

Losartan potassium

Losartan potassium is an angiotensin II receptor blocker acting on the AT 1 receptor subtype

DRUG

Placebo losartan capsule

Matching placebo losartan oral capsule

Sponsors & Collaborators

  • Johns Hopkins University

    collaborator OTHER

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    lead NIH

Principal Investigators

  • Edward Doo, MD · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-02
Primary Completion
2020-06-30
Completion
2020-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03467217 on ClinicalTrials.gov